Aurobindo Pharma Limited — Updates, 05-12-2024: Press Release

Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma, has received USFDA approval to manufacture and market Pazopanib Tablets, 200 mg. This product is bioequivalent to Novartis' Votrient Tablets and is expected to launch in Q4FY25. The market size for this product is estimated at approximately US$ 106 million for the twelve months ending October 2024, based on IQVIA data. This marks the 179th ANDA approval from Eugia Pharma, which includes eight tentative approvals, reinforcing the company’s capacity in oncology products. The tablets are specifically indicated for the treatment of adults with Advanced Renal Cell Carcinoma and Advanced Soft Tissue Sarcoma following prior chemotherapy. Investors should maintain a positive outlook on Aurobindo Pharma, given this approval could enhance revenue streams and market presence in the oncology segment.